The adult stem cell therapy developer AlloCure has moved from Salt Lake City all the way to Burlington, MA. Lean and mean with fewer than 10 workers, AlloCure also has a new CEO: Robert Brenner. "If we could develop a cell therapy for acute kidney injury, it would be a revolution," Brenner tells Xconomy. "People have been working on this for their entire professional careers." Story